证券代码：688068 证券简称：热景生物 公告编号：2026-007 北京热景生物技术股份有限公司 关于出售已回购股份进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 二、出售计划的实施进展 （一）因以下原因披露出售计划实施进展： 重要内容提示： 回购股份的基本情况 为维护公司价值及股东权益，北京热景生物技术股份有限公司（以下简称 "公司"）于2024年2 月8日至2024 年5月7 日期间累计回购公司股份2,893,010 股，占公司当前总股本的 3.12%，具体内容详见公司于 2024 年 5 月 9 日披露的 《北京热景生物技术股份有限公司关于股份回购实施结果暨股份变动公告》（公 告编号：2024-042）。上述回购的股份将于披露回购实施结果暨股份变动公告十 二个月后采用集中竞价交易方式出售。公司如未能在股份回购完成之后 36 个月 内实施上述用途，未使用部分应予以注销。 出售计划的进展情况 公司于 2025 年 12 月 23 日召开第四届董事会第八次会议，审议并通过《关 于出售部分已回购股份 ...

证券代码：688068 证券简称：热景生物 公告编号：2026-006 AA001 是一款由智源生物刘瑞田教授研发团队研制的单克隆抗体药物，适 用于阿尔茨海默病源性轻度认知障碍及轻中度阿尔茨海默病患者的治疗。AA001 单抗于 2025 年 1 月获得国家药品监督管理局的临床试验许可，顺利完成 Ia 期临 床试验后，并于 2025 年 12 月启动基于阿尔茨海默病受试者的Ⅰb 期临床试验。 1 截止本公告日，针对阿尔茨海默病疾病，仅有卫材/渤健联合开发的仑卡奈 单抗（lecanemab）和礼来研发的多奈单抗（Donanemab）获美国 FDA 完全批准 上市，并分别于 2024 年 1 月和 12 月获得我国药品监督管理局批准上市，用于治 疗因阿尔茨海默病引起的轻度认知功能障碍和阿尔茨海默病轻度痴呆。 北京热景生物技术股份有限公司 关于自愿披露参股公司创新药 AA001 单抗 Ib 期临床 研究完成首例阿尔茨海默病受试者入组给药的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，北京热景生物技术股份有限公司（以 ...

Group 1 - The core announcement is about the quarterly adjustment results of the Sci-Tech 50 and other indices, which will be implemented after the market closes on March 13 [1] - Three companies, including Keda Guandun Quantum Technology Co., Ltd., Shenzhen Zhongke Feimeng Technology Co., Ltd., and Zhongke Xingtai Co., Ltd., will be added to the Sci-Tech 50 Index, while ten other securities will be added to the Sci-Tech 100 Index [1] - After the adjustments, the total market capitalization of the Sci-Tech 50 Index will be 4.5 trillion yuan, covering 39% of the market, while the Sci-Tech 100 Index will have a total market capitalization of 2.7 trillion yuan, covering 24% of the market, resulting in a combined coverage of 63%, an increase of 1.1% [1] Group 2 - The Shanghai Stock Exchange has been enhancing its "one body, two wings" index system to improve the quality and diversity of indices, effectively supporting long-term capital inflow and national strategic initiatives [2] - The periodic adjustments of existing indices aim to optimize industry structures, with the weight of information technology and other "new economy" sectors increasing by 4.9% and 4.7% respectively by the end of 2024 [2] - The newly launched indices cover the entire market capitalization and industry chain of the Sci-Tech Board, guiding over 320 billion yuan into "hard technology" companies [2]

Group 1 - The Shanghai Stock Exchange and China Securities Index Co., Ltd. announced adjustments to the sample of the Sci-Tech Innovation 50 Index, effective after the market closes on March 13, 2026 [2] - GuoDun Quantum, ZhongKe FeiCe, and ZhongKe XingTu will be added to the Sci-Tech Innovation 50 Index, while Rejing Bio, Sry New Materials, and Junshi Biosciences, among 10 other securities, will be added to the Sci-Tech Innovation 100 Index [4]

Group 1 - The Shanghai Stock Exchange and China Securities Index Company announced a quarterly adjustment of the sample stocks for the Sci-Tech 50 and other Sci-Tech indices [1] - The Sci-Tech 50 Index will replace three sample stocks, specifically Guoshun Quantum, Zhongke Feimeng, and Zhongke Xingtou [1] - Additionally, ten securities including Rejing Bio, Sry New Materials, and Junshi Biosciences will be added to the Sci-Tech 100 Index [1] - The adjustments will take effect after the market closes on March 13 [1]

Group 1 - The core viewpoint of the article highlights that 热景生物, the first listed company in the IVD sector on the Sci-Tech Innovation Board, has experienced a significant decline in revenue and profitability following the peak of COVID-19 testing, leading to its first annual loss in 2024 [2] - In the latest performance report, the company reported a revenue of 408 million yuan, a year-on-year decrease of 20.2%, and a net profit attributable to shareholders of -211 million yuan, a decline of 10.22% [2] - The company attributed its performance pressure to factors such as asset impairment losses, increased R&D investment, and losses from external investments, alongside industry policy impacts like price reductions and decreased demand [2] Group 2 - In the context of ongoing losses, the company's controlling shareholder and related parties have reduced their holdings multiple times, cashing out over 700 million yuan through share reductions [3] - As of January 31, the company repurchased nearly 904,100 shares, accounting for 0.98% of its total share capital, at a cost of approximately 150 million yuan [3] - The company's stock price has dropped by 21.79% year-to-date as of February 27, reaching a new low of 123.71 yuan, despite a nearly 162% increase in stock price over the previous year [3] Group 3 - Analysts from 东吴证券 express optimism about the company's innovative pipeline in the cardiovascular field, highlighting potential in its subsidiaries' drug development [4] - The company has identified targets and produced pipelines in oncology, neurology, and cardiovascular areas, with unique antibody products that differentiate from competitors [4] - The subsidiaries are working on various innovative drug platforms, including a targeted small nucleic acid platform and dual-antibody drugs for cancer treatment [4]

Core Viewpoint - The healthcare sector is experiencing positive momentum, with the largest healthcare ETF (512170) showing strong performance and attracting significant net inflows of capital [1][8]. Group 1: ETF Performance - On February 27, the healthcare ETF (512170) initially rose over 1% and maintained a positive trend, outperforming the broader market [1][8]. - The ETF saw a net subscription of over 115 million yuan in the previous day, indicating strong investor interest [1][8]. - As of February 24, the healthcare ETF has a total fund size of 27.7 billion yuan, making it the largest in the healthcare sector [5][12]. Group 2: Company Earnings Reports - Huatai Medical reported an expected revenue of 2.584 billion yuan for 2025, representing a year-on-year increase of 25%, with a net profit of 821 million yuan, up 22% [3][10]. - Other companies within the ETF, such as United Imaging and Yirui Technology, also reported significant net profit growth rates exceeding 40% [3][10]. - In contrast, Hotgen Biotech is projected to incur a loss of over 200 million yuan [3][10]. Group 3: Stock Movements - Huatai Medical's stock surged over 11% in early trading, currently leading the sector with a nearly 7% increase [4][10]. - Other stocks like Yingke Medical and Meihua Medical also saw gains, while Jinsong Biological experienced a decline of over 2% [4][10].

Core Viewpoint - The company reported a significant decline in revenue and net profit for the fiscal year 2025, primarily due to industry policy impacts and increased R&D investments in its subsidiaries [1] Financial Performance - The company achieved an operating revenue of 407.69 million yuan, a decrease of 20.20% compared to the same period last year [1] - The net profit attributable to the parent company was -210.52 million yuan, with a net profit excluding non-recurring gains and losses of -258.11 million yuan [1] Industry Impact - The in vitro diagnostic industry faced challenges from centralized procurement policies, leading to a short-term decline in domestic prices and reduced demand, contributing to a revenue drop of 103.21 million yuan [1] - Adjustments in national tax policies for the industry further exacerbated the revenue decline [1] Asset Impairment - The company recognized an impairment loss of 38.01 million yuan related to its operating assets, including reagents and equipment, following its consistent impairment policy [1] Subsidiary Developments - The company increased its investment in the joint venture ShunJing Pharmaceutical, which has become a subsidiary and is included in the consolidated financial statements [1] - ShunJing Pharmaceutical continued to advance its innovative drug pipeline, with R&D expenditures amounting to 78.62 million yuan during the reporting period [1] Investment Losses - The company reported an investment loss of 13.51 million yuan from its joint ventures, including YaoJing Gene and ZhiYuan Bio, which have been increasing their R&D investments in the field of biopharmaceuticals [1]

Core Viewpoint - The company reported a significant decline in revenue and net profit for the fiscal year 2025, primarily due to industry policy impacts and increased competition in the in vitro diagnostics sector [1] Financial Performance - The company achieved an operating revenue of 407.69 million yuan, a decrease of 20.20% compared to the same period last year [1] - The net profit attributable to the parent company was -210.52 million yuan, with a net profit excluding non-recurring gains and losses of -258.11 million yuan [1] Industry Impact - The in vitro diagnostics industry faced challenges from centralized procurement policies, leading to a short-term decline in domestic prices and reduced demand, contributing to a revenue drop of 103.21 million yuan [1] - Changes in national tax policies for the industry also negatively affected revenue [1] Asset Impairment - The company recognized an impairment loss of 38.01 million yuan on related operating assets, including reagents and equipment, following its consistent impairment policy [1] Investments and R&D - The company increased its investment in the joint venture ShunJing Pharmaceutical, which became a subsidiary and was included in the consolidated financial statements [1] - ShunJing Pharmaceutical continued to advance its innovative drug pipeline, with R&D expenditures amounting to 78.62 million yuan during the reporting period [1] - The company also reported investment losses of 13.51 million yuan from joint ventures such as YaoJing Gene and ZhiYuan Bio, which increased their R&D investments in the field of biopharmaceuticals [1]

Core Viewpoint - The company reported a significant decline in revenue for the year 2025, indicating potential challenges in its business operations and market conditions [2] Financial Performance - The company achieved a total operating revenue of 407.6938 million yuan in 2025, representing a year-on-year decrease of 20.20% [2]